Cargando…

Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?

INTRODUCTION: Cardiovascular disease (CVD) is a significant cause of non-AIDS-related morbidity and mortality in HIV-positive individuals [1]. Management of CVD and associated risk factors in HIV are complicated by drug interactions [2]. Optimal management can require specialist input. A previous co...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolls, Sophie, Denneny, Emma, Marcus, Rebecca, O'Connell, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225426/
https://www.ncbi.nlm.nih.gov/pubmed/25397471
http://dx.doi.org/10.7448/IAS.17.4.19725
_version_ 1782343504572186624
author Rolls, Sophie
Denneny, Emma
Marcus, Rebecca
O'Connell, Rebecca
author_facet Rolls, Sophie
Denneny, Emma
Marcus, Rebecca
O'Connell, Rebecca
author_sort Rolls, Sophie
collection PubMed
description INTRODUCTION: Cardiovascular disease (CVD) is a significant cause of non-AIDS-related morbidity and mortality in HIV-positive individuals [1]. Management of CVD and associated risk factors in HIV are complicated by drug interactions [2]. Optimal management can require specialist input. A previous cohort review highlighted CVD, comorbidity and cardiovascular (CV) risk in our patients [3]. In response, a combined HIV and cardiovascular monthly clinic was established: an HIV consultant works in real time with a cardiologist. The clinic manages CV disease, complex CV co-morbidities e.g. refractory hypertension, hyperlipidaemia, and assesses primary prevention. A dietician works alongside the clinic. AIMS: Describe the clinic caseload; record clinic interventions and outcomes; recommend service development. MATERIALS AND METHODS: We conducted a retrospective notes review of patients attending the co-morbidity clinic from January 2012 to May 2014. Data collected: demographic, HIV, CVD, CV risk, investigations and clinical interventions. RESULTS: From a cohort of approximately 960 patients (70% African), 60 (6%) were seen in the co-morbidity clinic over the specified time period. Median age was 53 (range 24-80). Although 60% of our cohort is female, 43% (26/60) of the CVD clinic were female. 42 (70%) were African. The mean CD4 was 560 (range 48-1339). All patients were on ART and 6 (10%) had a detectable viral load > 400 copies/mL. Clinic caseload: i) CVD: 9 had a prior CV event (ACS or CVA); 5 had CCF; new diagnoses included LVH (2), cardiac dysfunction (6); AF (2); atrial thrombus (1). ii) Co-morbidities: 48(80%) had hypertension – 10 (16.6%) were on quadruple therapy; 17 (28%) had diabetes; 35 (58%) were on a statin. Three had their smoking status clearly documented. Seventeen (28%) were referred to the dietician. Investigations included echo, 24-hour BP/ tape, CT angio, cardiac MR. CONCLUSIONS: The joint clinic facilitated real-time decision making on clinical interventions. Patient access to cardiac investigations was expedited. Patients attended fewer outpatient appointments. Both cardiology and HIV clinicians preferred the benefits of joint working. Clinical outcomes were difficult to assess and will need further definition. Recommendations for development include: improved CV risk assessment, improved outcome measures, links to smoking cessation services.
format Online
Article
Text
id pubmed-4225426
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42254262014-11-13 Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where? Rolls, Sophie Denneny, Emma Marcus, Rebecca O'Connell, Rebecca J Int AIDS Soc Poster Sessions – Abstract P193 INTRODUCTION: Cardiovascular disease (CVD) is a significant cause of non-AIDS-related morbidity and mortality in HIV-positive individuals [1]. Management of CVD and associated risk factors in HIV are complicated by drug interactions [2]. Optimal management can require specialist input. A previous cohort review highlighted CVD, comorbidity and cardiovascular (CV) risk in our patients [3]. In response, a combined HIV and cardiovascular monthly clinic was established: an HIV consultant works in real time with a cardiologist. The clinic manages CV disease, complex CV co-morbidities e.g. refractory hypertension, hyperlipidaemia, and assesses primary prevention. A dietician works alongside the clinic. AIMS: Describe the clinic caseload; record clinic interventions and outcomes; recommend service development. MATERIALS AND METHODS: We conducted a retrospective notes review of patients attending the co-morbidity clinic from January 2012 to May 2014. Data collected: demographic, HIV, CVD, CV risk, investigations and clinical interventions. RESULTS: From a cohort of approximately 960 patients (70% African), 60 (6%) were seen in the co-morbidity clinic over the specified time period. Median age was 53 (range 24-80). Although 60% of our cohort is female, 43% (26/60) of the CVD clinic were female. 42 (70%) were African. The mean CD4 was 560 (range 48-1339). All patients were on ART and 6 (10%) had a detectable viral load > 400 copies/mL. Clinic caseload: i) CVD: 9 had a prior CV event (ACS or CVA); 5 had CCF; new diagnoses included LVH (2), cardiac dysfunction (6); AF (2); atrial thrombus (1). ii) Co-morbidities: 48(80%) had hypertension – 10 (16.6%) were on quadruple therapy; 17 (28%) had diabetes; 35 (58%) were on a statin. Three had their smoking status clearly documented. Seventeen (28%) were referred to the dietician. Investigations included echo, 24-hour BP/ tape, CT angio, cardiac MR. CONCLUSIONS: The joint clinic facilitated real-time decision making on clinical interventions. Patient access to cardiac investigations was expedited. Patients attended fewer outpatient appointments. Both cardiology and HIV clinicians preferred the benefits of joint working. Clinical outcomes were difficult to assess and will need further definition. Recommendations for development include: improved CV risk assessment, improved outcome measures, links to smoking cessation services. International AIDS Society 2014-11-02 /pmc/articles/PMC4225426/ /pubmed/25397471 http://dx.doi.org/10.7448/IAS.17.4.19725 Text en © 2014 Rolls S et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Sessions – Abstract P193
Rolls, Sophie
Denneny, Emma
Marcus, Rebecca
O'Connell, Rebecca
Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title_full Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title_fullStr Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title_full_unstemmed Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title_short Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where?
title_sort tackling cardiovascular co-morbidities in hiv-positive patients: who, how and where?
topic Poster Sessions – Abstract P193
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225426/
https://www.ncbi.nlm.nih.gov/pubmed/25397471
http://dx.doi.org/10.7448/IAS.17.4.19725
work_keys_str_mv AT rollssophie tacklingcardiovascularcomorbiditiesinhivpositivepatientswhohowandwhere
AT dennenyemma tacklingcardiovascularcomorbiditiesinhivpositivepatientswhohowandwhere
AT marcusrebecca tacklingcardiovascularcomorbiditiesinhivpositivepatientswhohowandwhere
AT oconnellrebecca tacklingcardiovascularcomorbiditiesinhivpositivepatientswhohowandwhere